LFCR
Next earnings: Jul 31, 2026
Signal
Bearish Setup2
Price
1
Move-3.30%Selling pressure
Volume
1
Volume0.5× avgNormal activity
Technical
1
RSIRSI 41Momentum negative
PRICE
Prev Close
4.55
Open
4.56
Day Range4.38 – 4.56
4.38
4.56
52W Range3.63 – 8.98
3.63
8.98
14% of range
VOLUME & SIZE
Avg Volume
327.1K
FUNDAMENTALS
P/E Ratio
-3.5x
Not profitable
EPS (TTM)
Div Yield
No dividend
Performance
1D
-3.30%
5D
-6.98%
1M
-18.22%
3M
-37.85%
6M
-44.72%
YTD
-46.21%
1Y
-34.43%
Worst: YTD (-46.21%)
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +4% YoY
Valuation
FAIR
P/E not available
Health
MODERATE
CR 3.8 · FCF $0.28/sh
Bullish
Key MetricsTTM
Market Cap$165.04M
Revenue TTM$135.16M
Net Income TTM-$34.09M
Free Cash Flow$10.47M
Gross Margin31.2%
Net Margin-25.2%
Operating Margin-0.1%
Return on Equity-146.7%
Return on Assets-15.1%
Debt / Equity7.23
Current Ratio3.79
EPS TTM$-0.91
Alpha SignalsFull Analysis →
What Moves This Stock

New CDMO contract announcements and client pipeline visibility, particularly multi-year supply agreements with biotech/pharma clients

Facility capacity utilization rates and manufacturing efficiency metrics (batch success rates, turnaround times)

HA pricing trends and competitive dynamics with Asian suppliers (particularly Chinese fermentation producers)

Regulatory inspection outcomes and FDA compliance status for the Chaska facility

Macro Sensitivity
Economic Cycle

low-to-moderate - Pharmaceutical manufacturing demand is relatively recession-resistant as drug development and production continue through economic cycles. However, biotech funding conditions affect client pipeline, and elective medical procedures (orthopedic injections, aesthetic treatments using HA) show modest sensitivity to consumer discretionary spending. The company's negative margins create vulnerability to prolonged downturns that could constrain client capital allocation.

Interest Rates

Rising interest rates negatively impact Lifecore through multiple channels: (1) higher financing costs on the company's substantial debt load (Debt/Equity of 3.74), pressuring already-negative cash flow; (2) reduced biotech/pharma client funding as venture capital and IPO markets tighten, potentially delaying CDMO projects; (3) lower valuation multiples for unprofitable growth companies. The 2-year Treasury yield directly affects refinancing risk and working capital costs.

Key Risks

CDMO commoditization risk as manufacturing capacity expands globally, particularly in lower-cost geographies (India, China), compressing pricing power for standard fill-finish services

HA market pricing pressure from Asian fermentation producers with 30-50% cost advantages, threatening margin sustainability in the commodity HA segment

Regulatory risk from FDA inspection findings or quality system deficiencies that could halt production or limit new client onboarding

Investor Profile

value/turnaround - The stock appeals to distressed/special situations investors betting on operational turnaround, capacity utilization improvement, and margin expansion from current depressed levels. Small-cap healthcare specialists may see CDMO consolidation potential or niche positioning value. Not suitable for income investors (no dividend) or risk-averse growth investors given negative profitability and execution risk.

Watch on Earnings
Federal Funds Rate and 2-Year Treasury yield (financing cost impact on debt servicing and biotech client funding)High-yield credit spreads (OAS) as indicator of refinancing conditions and distressed company riskBiotech IPO and venture funding volumes (leading indicator of CDMO demand pipeline)FDA warning letters and inspection outcomes for CDMO facilities (competitive positioning indicator)
Health Radar
1 strong5 concern
19/100
Liquidity
3.79Strong
Leverage
7.23Concern
Coverage
-0.0xConcern
ROE
-146.7%Concern
ROIC
-0.0%Concern
Cash
$8MConcern
ANALYST COVERAGE7 analysts
BUY
+36.4%upside to target
Buy
571%
Hold
229%
5 Buy (71%)2 Hold (29%)0 Sell (0%)
Full report →
Stock Health
Composite Score
2 of 5 signals bullish
3/10
Technicals
RSI RangeRSI 41 — Bearish momentum
Volume
Volume FlowDistribution — institutional selling
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 3.79 — healthy liquidity
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentAug 31, 2026
In 106 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendDeath Cross · 50D trails 200D by 23.3%

-18.0% vs SMA 50 · -37.1% vs SMA 200

Momentum

RSI41.5
Momentum fading
MACD-0.14
Below zero — bearish pulse · expanding
Market Position
Price Levels
52W High
$8.98+104.1%
EMA 200
$6.59+49.8%
EMA 50
$5.29+20.3%
Current
$4.40
52W Low
$3.63-17.5%
52-Week RangeNear 52-week low
$3.6314th %ile$8.98
Squeeze SetupVolume-based
Distribution Pressure

Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.

20-Day Money Flow
Acc days:0
Dist days:0
Edge:Even
Volume Context
Avg Vol (50D)381K
Recent Vol (5D)
201K-47%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 4 analysts
Analyst revisions:EPS↓ Revised DownRevenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$127.8M
$126.1M$129.6M
-$1.33
±8%
Low2
FY2026(current)
$75.1M
$73.1M$77.6M
-41.2%-$0.48
±5%
Moderate3
FY2027
$122.2M
$119.5M$124.3M
+62.6%-$1.04
±3%
Moderate4
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryLFCR
Last 8Q
-9.7%avg beat
Beat 4 of 8 quartersMissed 4 Estimates falling
+7%
Q1'25
-36%
Q2'25
-11%
Q3'25
+3%
Q4'25
+45%
Q1'26
+41%
Q1'26
-48%
Q2'26
-79%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
English Aron R.10 Percent Own…
$649K
May 23
SELL
English Aron R.10 Percent Own…
$7.4M
May 27
SELL
English Aron R.10 Percent Own…
$1.1M
May 28
SELL
English Aron R.10 Percent Own…
$86K
May 13
SELL
English Aron R.10 Percent Own…
$36K
May 8
SELL
English Aron R.10 Percent Own…
$5K
May 9
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
WYNNEFIELD CAPITAL INC
4.7M
2
Legion Partners Asset Management, LLC
4.5M
3
Greenhaven Road Investment Management, L.P.
3.5M
4
325 CAPITAL LLC
2.2M
5
BlackRock, Inc.
1.9M
6
GRIZZLYROCK CAPITAL, LLC
827K
7
GEODE CAPITAL MANAGEMENT, LLC
815K
8
MORGAN STANLEY
765K
News & Activity

LFCR News

About

landec corporation (nasdaq:lndc) is a leading innovator of diversified health and wellness solutions within the packaged food and biomaterial markets. apio, landec's food business, is the leader in branded, packaged fresh vegetables in north america, utilizing its proprietary breatheway® packaging technology to naturally extend the shelf life of fresh produce. apio combines this technology with the capabilities of a large national fresh produce supplier to offer healthy fresh vegetable products under the eat smart® brand to consumers through club and retail grocery stores. lifecore biomedical, landec's biomaterial business, is a fully integrated contract development and manufacturing organization (cdmo) that offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for fda regulated medical devices and drugs to customers for applications in a wide array of markets including ophthalmic, orthopedic and oncology. for more information abo

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Albert Bolles
Parker K. JavidVice President
Paul JosephsPresident, Chief Executive Officer & Director
Ryan D. LakeExecutive Vice President & Chief Financial Officer
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
LFCR
$4.40-3.30%$165M+47.2%-3004.4%1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.30%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-3.01%50.3+341856.6%-3931.1%1500